FDA Approves the Single-Dose Flu-Drug

The US Food and Drug Administration has taken an important decision that would change how the season of Flu is seen in the United States. FDA has approved a single-dose drug that can be used for treating Flu. Till now, various methods were used for treating the same disease, but this drug would revolutionize the whole process by offering better results in a shorter period of time. Xofluza has been designed in such a way that a single dose would be sufficient to treat the various impacts of uncomplicated flu. It can be used for a wide age group from 12 and beyond. It’s an antivirus drug that has an impressive amount of performance as well.

“This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA in nearly 20 years. With thousands of people getting the flu every year, and many people becoming seriously ill, having safe and effective treatment alternatives is critical. This novel drug provides an important, additional treatment option,” said Scott Gottlieb, who is the FDA Commissioner. Of course, FDA believes that the drug would be a huge help for people who are suffering from the various issues of the flu. Flu is caused by the influenza virus and the drug has to be taken within 48 hours of symptoms.

Experts in the matter are really impressed by the move from FDA. In fact, some believe that it was a bit late from the part of FDA to take such a decision, which would save thousands of lives per year. This antiviral drug is much better than the current options in the market, given that Xofluza will be taking on the virus, instead of blocking the paths. This method is also expected to contract the length of the symptoms such as a headache and other issues that people suffer due to flu.

Over 4 years’ experience in the research industry. Experience with research and consulting projects, catering to domains such as ICT, Health & Pharma, and packaging. Managed projects on both B2B as well as B2C perspective, which includes consumer preference analysis, interviews with key executives, etc.